IMULAN Expands Veterinary ApSTAR Cancer Program

Imulan BioTherapeutics, LLC has extended the term of their exclusive license agreement with ImmunoPhotonics Inc.; for the veterinary cancer laser system based on on-going clinical trials in dogs and cats. The new portable laser device, termed apSTAR (Autologous Patient Specific Tumor Antigen Response), uses a specific wavelength to activate an immune response against the tumor cells. IMULAN’s subsidiary, Veterinary Cancer Therapeutics, is focused on hemangiosarcoma, fibrosarcoma, mast cell tumors, melanoma, osteosarcoma, and other prevalent cancers in dogs, cats and horses. In previous in vivo cancer models, apSTAR has shown the ability to induce long term tumor immunity and improve primary and metastatic tumor regression. Immunophotonics, Inc. was established in 2008 by a team of experts in laser physics and immunotherapy as a US-based research-oriented company whose main objective is to develop and introduce Laser-assisted Immunotherapy, a promising new treatment method for metastatic tumors. Imulan develops unique, precision immune regulating compounds for infectious, autoimmune, and immune mediated diseases in small and large animal medicine. For more information about Imulan, please visit ,a href="http://www.imulan.com">www.imulan.com.

More from

• Animus launches SkinBond Multi for enhanced wound care
• IVC Evidensia reports 82% cut in Farm antibiotic use and 20% carbon emissions reduction
• Vet professionals flock to sign up to transformative locum platform
• The ProSalus Foundation launches urgent appeal for UK vets to support Ukrainian colleagues
• Vetsure Named Business of the Year at 2025 SME National Business Awards